Brought to you by 
Management buy-out at Qiagen Marseille creates newco HalioDx
30 Mar 2015
Executive Summary
Management of Qiagen NV division Qiagen Marseille SA have formed a new company, HalioDx, through a buy-out. All assets and liabilities will transfer, with the exception of an IP portfolio, research tax credit, and cash assets.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Management buy-out at Qiagen Marseille creates newco HalioDx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice